Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
MBRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.64M
- P/E (TTM)
- 0.05
- EPS (TTM)
- $8.98
- Dividend yield
- None
- 52-week range
- 0.161 – 15.75
- Day range
- 0.4107 – 0.4415
- Volume / Avg
- 264.61K / 1.28M
- Beta
- —
- Shares outstanding
- 20.39M
52-week range
MBRX stock today
Shares of Moleculin Biotech (MBRX) finished lower on Oct 8 at $0.424, a drop of 3.39% or $0.0149 per share, versus the S&P 500's 0.47% decline. Trading was light, with 264.61K shares changing hands, about 21% of the average daily volume. Shares are 97.3% below their 52-week high of $15.75 and 163.4% above the 52-week low of $0.161, near the bottom of the past year's range.
Moleculin Biotech trades at 0.0x its trailing twelve-month earnings per share of $8.98.
Summary generated from market data by MetaCap's automated system. Methodology
About Moleculin Biotech
Company profileMoleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Walter V. Klemp
- Headquarters
- Houston, TX
- Employees
- 17
- IPO year
- 2016
- Website
- moleculin.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$12.00+2730.19%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Moleculin Biotech peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JAGXJaguar Health Inc. | 4.53 | -9.40% | $8.81M | vs MBRX |
| MTVAMetaVia Inc. | 1.34 | -8.22% | $8.83M | vs MBRX |
| CALCCalciMedica Inc. | 1.30 | -12.16% | $8.88M | vs MBRX |
| ENSCEnsysce Biosciences Inc. | 0.458 | +6.66% | $8.91M | vs MBRX |
| IMRNImmuron Limited ADR | 1.11 | +1.83% | $8.96M | vs MBRX |
| AZTRAzitra Inc | 0.132 | 0.00% | $8.00M | vs MBRX |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | -1.47% | $7.82M | vs MBRX |
| FBLGFibroBiologics Inc. | 1.11 | -2.63% | $7.72M | vs MBRX |
Indexes, lists and sector
Appears in lists
Moleculin Biotech stock FAQ
What is Moleculin Biotech's stock price today?
MBRX last traded at $0.424 as of Oct 8, 4:00 PM EDT, down 3.39% on the day. Prices are delayed at least 15 minutes.
What is MBRX's P/E ratio?
MBRX trades at a trailing P/E ratio of 0.05.
Who is Moleculin Biotech's CEO?
Mr. Walter V. Klemp is the chief executive officer of Moleculin Biotech Inc., which has about 17 employees.
What is the MBRX 52-week high?
The 52-week high for MBRX is $15.75 and the 52-week low is $0.161. The stock is currently 97.3% below its high.